Prenetics Global (PRE) Projected to Announce Earnings on Tuesday

Prenetics Global (NASDAQ:PRE) will likely be posting its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect the company to announce earnings of ($0.48) per share and revenue of $49.85 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 8:30 AM ET.

Prenetics Global (NASDAQ:PRE) last issued its quarterly earnings data on Wednesday, June 10th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.07). The company had revenue of $35.95 million for the quarter, compared to analyst estimates of $36.00 million. Prenetics Global had a negative return on equity of 20.33% and a negative net margin of 62.45%.

Prenetics Global Trading Up 3.0%

PRE stock opened at $18.80 on Tuesday. The stock has a market cap of $317.16 million, a PE ratio of -4.10 and a beta of 0.26. Prenetics Global has a 1 year low of $7.18 and a 1 year high of $23.63. The stock has a 50-day moving average price of $19.29 and a two-hundred day moving average price of $18.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in Prenetics Global in the fourth quarter valued at approximately $1,302,000. Millennium Management LLC bought a new stake in shares of Prenetics Global in the fourth quarter worth $810,000. Marshall Wace LLP acquired a new stake in shares of Prenetics Global in the fourth quarter valued at about $788,000. Goldman Sachs Group Inc. bought a new stake in Prenetics Global in the fourth quarter valued at approximately $665,000. Finally, UBS Group AG boosted its stake in shares of Prenetics Global by 581.9% in the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after purchasing an additional 39,733 shares during the last quarter. Institutional investors own 25.01% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on PRE shares. Benchmark raised their price target on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen downgraded shares of Prenetics Global from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research note on Friday, July 17th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Prenetics Global presently has an average rating of “Moderate Buy” and a consensus target price of $34.25.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.